Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Foods ; 12(14)2023 Jul 19.
Artículo en Inglés | MEDLINE | ID: mdl-37509832

RESUMEN

Chitooligosaccharide (COS), found in both insects and marine sources, has several bioactivities, such as anti-inflammation and antioxidant activities. However, the mechanism of shrimp shell COS on retardation of inflammatory and antioxidant effects is limited. Therefore, the aim of this study is to examine the mechanism of the aforementioned activities of COS in LPS-activated RAW264.7 macrophage cells. COS significantly improved cell viability in LPS-activated cells. COS at the level of 500 µg/mL could reduce the TNF-α, NO and IL-6 generations in LPS-activated cells (p < 0.05). Furthermore, COS could reduce ROS formation, NF-κB overactivation, phosphorylation of Erk1/2 and Akt and Nrf2/HO-1 in LPS-exposed cells. These results indicate that COS manifests anti-inflammatory activity and antioxidant action via NF-κB, Erk1/2, Akt and Nrf2/HO-1 signaling with an increasing relevance for inflammatory disorders.

2.
Foods ; 11(17)2022 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-36076858

RESUMEN

Alzheimer's disease is characterized by a progressive loss of memory and cognition. Accumulation of amyloid-beta (Aß) in the brain is a well-known pathological hallmark of the disease. In this study, the ethanolic extract of white shrimp (Litopenaous vannamei) shells and the ethanolic extract-loaded liposome were tested for the neuroprotective effects on Aß1-42-induced memory impairment in rats. The commercial astaxanthin was used as a control. Treatment with the ethanolic extract of shrimp shells (EESS) at the dose of 100 mg/kg BW showed no protective effect in Aß-treated rats. However, treatment with an EESS-loaded liposome at the dose of 100 mg/kg BW significantly improved memory ability in Morris water maze and object recognition tests. The beneficial effect of the EESS-loaded liposome was ensured by the increase of the memory-related proteins including BDNF/TrkB and pre- and post-synaptic protein markers GAP-43 and PSD-95 as well as pErk1/2/Erk1/2 in the cortex and hippocampus. These findings indicated the neuroprotective effects of the EESS-loaded liposome on Aß-induced memory impairment in rats. It produced beneficial effects on learning behavior probably through the function of BDNF/TrkB/pErk1/2/Erk1/2 signaling pathway and subsequently the upregulation of synaptic proteins. The present study provided evidence that the neuroprotective property of the ESSE-loaded liposome could be a promising strategy for AD protection.

3.
Toxicol In Vitro ; 83: 105410, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-35675846

RESUMEN

Besides being anti-diabetic drug, metformin also has anti-proliferation and growth in several tumors; however, details of possible mechanism have not been elucidated. Here, we investigated the effects of metformin in neuroblastoma which has been termed as extra-cranial solid tumor that is due to a differentiation block with more stemness. The results showed that 5 mM metformin inhibited cell cycle progression at G0/G1 phase. Metformin also induced morphological differentiation of neuroblastoma into neuron-like phenotypes by which upregulation of MAP2, ß-tubulin III and tyrosine hydroxylase expressions with no significant difference to retinoic acid (RA)-treated cells. We also tested proliferative, growth and self-renewal ability after neuroblastoma being differentiated by metformin for 24 h. The proliferative rate, sizes and numbers of colonies and spheroids were significantly reduced in differentiated neuroblastoma compared to undifferentiated neuroblastoma. A significant increase of ROS and ADP/ATP ratio with decreased mitochondrial membrane potential (MMP) were observed in metformin-treated cells, indicating mitochondrial biogenesis and metabolic change during metformin-mediated differentiation. The further studies exhibited that p-Erk1/2 and Cdk5 levels were reduced in metformin treatment whereas using PD98095 and roscovitine, selectively inhibited Erk1/2 and Cdk5, respectively, significantly increased neurite length and MAP2 expression. In addition, cell proliferation was decreased by cell cycle arrested at G0/G1 phase. Taken together, this study suggests the inhibitory effects of metformin against proliferation and growth of neuroblastoma due to induced morphological differentiation may be through Erk1/2 and Cdk5 pathways. Therefore, metformin might be eventually considered as a differentiation agent for neuroblastoma treatment in term of differentiation therapy.


Asunto(s)
Metformina , Neuroblastoma , Diferenciación Celular , Línea Celular Tumoral , Humanos , Metformina/farmacología , Neuroblastoma/metabolismo , Tretinoina/farmacología
4.
Molecules ; 26(5)2021 Feb 28.
Artículo en Inglés | MEDLINE | ID: mdl-33671094

RESUMEN

Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons. The cause of PD is still unclear. Oxidative stress and mitochondrial dysfunction have been linked to the development of PD. Luteolin, a non-toxic flavonoid, has become interested in an alternative medicine, according to its effects on anti-oxidative stress and anti-apoptosis, although the underlying mechanism of luteolin on PD has not been fully elucidated. This study aims to investigate whether luteolin prevents neurotoxicity induction by 1-methyl-4-phenylpyridinium iodide (MPP+), a neurotoxin in neuroblastoma SH-SY5Y cells. The results reveal that luteolin significantly improved cell viability and reduced apoptosis in MPP+-treated cells. Increasing lipid peroxidation and superoxide anion (O2-), including mitochondrial membrane potential (Δψm) disruption, is ameliorated by luteolin treatment. In addition, luteolin attenuated MPP+-induced neurite damage via GAP43 and synapsin-1. Furthermore, Cdk5 is found to be overactivated and correlated with elevation of cleaved caspase-3 activity in MPP+-exposed cells, while phosphorylation of Erk1/2, Drp1, Fak, Akt and GSK3ß are inhibited. In contrast, luteolin attenuated Cdk5 overactivation and supported phosphorylated level of Erk1/2, Drp1, Fak, Akt and GSK3ß with reducing in cleaved caspase-3 activity. Results indicate that luteolin exerts neuroprotective effects via Cdk5-mediated Erk1/2/Drp1 and Fak/Akt/GSK3ß pathways, possibly representing a potential preventive agent for neuronal disorder.


Asunto(s)
1-Metil-4-fenilpiridinio/metabolismo , Quinasa 5 Dependiente de la Ciclina/metabolismo , Luteolina/farmacología , Fármacos Neuroprotectores/farmacología , Enfermedad de Parkinson/tratamiento farmacológico , Apoptosis/efectos de los fármacos , Neuronas Dopaminérgicas/efectos de los fármacos , Dinaminas/metabolismo , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Proteína-Tirosina Quinasas de Adhesión Focal/metabolismo , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Humanos , Luteolina/metabolismo , Membranas Mitocondriales/metabolismo , Fármacos Neuroprotectores/metabolismo , Estrés Oxidativo , Fosforilación , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA